scholarly journals A Comparative Study on the Effects of Ketofol, Dexmedetomidine, and Isofol in Anesthesia of Candidates for Dilatation and Curettage

2022 ◽  
Vol 11 (6) ◽  
Author(s):  
Mahzad Yousefian ◽  
Ali Mohammadian Erdi ◽  
Negin Haghshenas

Background: Dilatation and curettage (D & C) is one of the relatively common surgeries among women. Familiarity with the analgesics, along with their different uses and specific characteristics, can help to determine the best and most appropriate drug to control pain in the patients. Objectives: This study aimed to compare the effects of ketofol, dexmedetomidine, and isofol in anesthesia of candidates for D & C. Methods: In this double-blind clinical trial, 150 candidates for D & C surgeries with ASA class 1 and 2 were included. Patients were randomly divided into three groups. The first group received ketamine + propofol, the second group received dexmedetomidine, and the third group received isofol (isoflurane + propofol). Any hemodynamic changes or respiratory disorders, including apnea or hypoventilation, drop in the level of blood oxygen saturation, and the need for respiratory support, were recorded and compared. Results: Hypoventilation was observed in 47 patients in isofol group, 18 in the dexmedetomidine group, and 42 in ketofol group. Also, 48 patients in the isofol group, eight in the dexmedetomidine group, and 33 in the ketofol group experienced apnea. Moreover, 17 patients in the dexmedetomidine group, 35 in the ketofol group, and eight in the isofol group experienced bradycardia. The rate of bradycardia was significantly higher in the dexmedetomidine group (70%) compared to the other two groups, and the rate of hypotension was significantly higher in the isofol group (P = 0.001). Conclusions: According to the results, dexmedetomidine was associated with fewer complications during general anesthesia in D & C surgery.

1996 ◽  
Vol 85 (02) ◽  
pp. 66-70 ◽  
Author(s):  
Veronique M.A. Van Erp ◽  
Martien Brands

AbstractIn a clinic in Tamale (Ghana, Northern Region) patients with malaria were treated with homoeopathic drugs in an open study (n=75), of whom 90.7% (n=68) showed clinical improvement.Subsequently in a randomized, double-blind, clinical trial, one group (n=30) received homoeopathic drugs, of which 83.3% improved clinically, whereas the other group (n=25) received chloroquine with improvement in 72% patients. This difference is not statistically significant due to the limited samples. The results do, however, suggest further research with larger groups.


2015 ◽  
Vol 39 (4) ◽  
pp. 382-386 ◽  
Author(s):  
D Flores-Castillo ◽  
R Martínez-Rider ◽  
S Ruiz-Rodríguez ◽  
A Garrocho-Rangel ◽  
J Lara-Guevara ◽  
...  

Aim: The objective of this study was to evaluate the efficacy of subcutaneous (SC) sedation using midazolam with and without ketamine in non-cooperative pediatric patients undergoing dental treatment. Study Design: A prospective, randomized, controlled, double-blind, crossover pilot clinical trial was carried out in 13 children, aged between 17–46 months, ASA l, Frankl 1. Two sedation schemes were administered SC: Midazolam alone (M), and a combination of Midazolam-Ketamine (MK). Both regimens were administered to the same patient in two consecutive treatment sessions, in accordance with a random assignment. Overall behavior, movement, and crying were assessed according to the modified Houpt scale. Heart rate, blood pressure, blood oxygen saturation, and possible side effects were also monitored. Results: The percentage of non-crying children was always higher in the treatment with MK compared with the treatment with M, but without a significant statistical difference. Regarding variable body movement, the percentage of children without movement was higher in the MK group, although only up to minute 10; no significant differences were found at 20, 30, and 40 minutes, and from minute 40, body movement was lower in the M group. Conclusions: Midazolam alone and the midazolam-ketamine combination administered subcutaneously resulted in a safe and efficient pharmacological method for providing moderate sedation to non-cooperative pediatric patients undergoing dental treatment.


1987 ◽  
Author(s):  
M Moriau ◽  
E Lavenne-Pardonge ◽  
C H Col-De Beys

Three prospective studies have been performed with piracetam (Nootropil ®-) in the treatment of Raynaud disease and syndromes.The first one, realized in 20 cases of Raynaud disease established that 8 g piracetam daily was the optimal dosage necessary to obtain a significant clinical, ultrasonic and biologic improvement.In the second one, 58 cases of Raynaud syndromes (47 idiopathic and 11 associated with systemic disease) were treated with 8 g daily piracetam during 6 to 12 months. A clinical and ultrasonic improvement was observed in 75 and 80 % of the cases and a normalisation of the disturbed platelet functions (36/58) in 88 %. Moreover a benefic rheologic effect was noted and related to the membrane deformability, the antiplatelet and the Von Willebranc factor synthese or release inhibiting activity of piracetamThe third one realized in cross over in 30 cases of Raynaud syndromes compare the effects of piracetam alone (dosage 8 g daily) with the combination piracetam (4 g daily) - aspirin (100 mg daily) or with other drugs like buflomedil, calcium antagonists and ketanserine.A synergic effect was obtained with the combination piracetam -aspirine and piracetam alone seems to be more efficient than the other drugs.A fourth double blind study is actually performed


Author(s):  
MC. de la Barrera-Nunez ◽  
RM. Yanez-Vico ◽  
A. Batista-Cruzado ◽  
JM. Heurtebise-Saavedra ◽  
R. Castillo-de Oyague ◽  
...  

Trials ◽  
2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Gholamreza Askari ◽  
Babak Alikiaii ◽  
Davood Soleimani ◽  
Amirhossein Sahebkar ◽  
Mahdiye Mirjalili ◽  
...  

Abstract Objectives This study aims to investigate the efficacy of curcumin-piperine co-supplementation on oxidative stress factors, clinical symptoms, and mortality rate in patients with coronavirus (COVID-19) admitted to the intensive care unit (ICU). Trial design This study is a randomized, placebo-controlled, double-blind, parallel-arm clinical trial. Participants The study participants will be recruited from patients admitted to the ICU of Al-Zahra hospital with a definitive diagnosis of COVID-19. The inclusion criteria are aged between 20 and 75 years, confirmation of COVID-19 based on the PCR test, and admitted to the ICU. The exclusion criteria include the present use of parenteral nutrition support, a history of underlying diseases such as congenital disorders, immune diseases, renal and hepatic insufficiency, and pancreatitis, a history of sensitivity to herbal remedies such as turmeric and pepper, and regular use of anticoagulant drugs such as warfarin. This study will be performed in the Al-Zahra hospital, an academic hospital affiliated with Isfahan University of Medical Sciences, Isfahan, Iran. Intervention and comparator Sixty eligible patients will be randomly assigned, in a 1:1 ratio, to receive curcumin-piperine capsules (three capsules/day; each capsules containing 500 mg curcumin plus 5 mg piperine; in total 1500 mg curcumin and 15 mg piperine/daily) for seven days (n=30) or matching placebo capsules (three capsules/day; each capsules containing 505 mg maltodextrin; totally 1515 mg, maltodextrin/ daily) for same duration (n=30). Capsules will be administered after oral or enteral feeding at 9, 15 and 21 o’clock. Main outcomes The primary outcome is the time from initiation of supplementation (curcumin-piperine or placebo) to normalization of fever, respiratory rate, and blood oxygen saturation. The secondary outcomes are the mortality rate, length of stay in ICU, temperature, levels of blood oxygen saturation, ventilator dependency, respiratory rate, levels of C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), levels of liver markers (ALT, AST, LDH), and levels of kidney function markers (BUN, Creatinine). Follow up All of the parameters will be assessed at baseline and end of the study (7 days intervention). In addition, the rate of mortality will be collected after 4 weeks (28 days’ mortality in the ICU, 4 weeks follow up). Randomisation Eligible patients will be randomly assigned to either the intervention group (Curcumin-piperine) or the control group (Placebo). Randomization sequences will be generated using an electronic table of random numbers to allocate the included participants into either control or intervention groups (in a 1:1 ratio) using the stratified block randomization method. Stratification was conducted according to sex (male and female), with a block size of four. The allocation sequences will be prepared by an independent statistician and will be kept inside sealed, opaque, and consecutively numbered envelopes. Participants, investigators, nurses, and physicians will be unaware of the trial-group assignment. Blinding (masking) This study is a double-blind clinical trial (participants, investigators, nurses, and physicians). The curcumin-piperine and placebo supplements will be similar in the terms of texture, taste, color, odor, and weight. Both tablets will be provided in containers that are completely identical in weight, shape, labeling, and packaging. All participants, investigators, nurses, and physicians will be unaware of the trial-group assignment. Numbers to be randomised (sample size) The sample size is estimated at 60 participants, including 30 patients in the intervention group and 30 patients in the placebo group. Trial Status The protocol is Version 2, registered on May 13, 2021. Recruitment began May 20, 2021, and is anticipated to be completed by September 20, 2021. Trial registration This trial has been registered in Iranian Registry of Clinical Trials (IRCT) with the title of “Evaluation of the effect of curcumin-piperine supplementation in patients with coronavirus admitted to the intensive care unit (ICU): a double-blind clinical trial study”. IRCT registration number is IRCT20121216011763N52. The registration date was May 13, 2021. Full Protocol The full protocol is attached as an additional file, accessible from the Trials website (File 1). In the interest of expediting the dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.


1998 ◽  
Vol 65 (1_suppl) ◽  
pp. 25-27
Author(s):  
F. Mantovani ◽  
E. Patelli ◽  
F. Colombo

Impairment of male sexual function is often associated with reduction in libido and can also occur at a relatively young age (30–50 years). In these cases pharmacological treatment may be clinically important. The effectiveness of the association L-arginine, fluid ginseng-guaranà and dried royal jelly was assessed. The choice of active ingredients was mainly based on their complete lack of side effects. A comparative double blind experimental model of research was used, patients being randomised into two groups. L-arginine HCL 2 g x 3 daily, dried royal jelly 200 mg, fluid ginseng 200 mg and guaranà 40 mg were given to 50 patients for two months. The other patients received a placebo. Clinical examination was repeated at monthly intervals. Treatment resulted in a significant improvement of the “libido intensity” symptom at the second and third control. An improvement in erectile maintenance was also noted at the third visit and, to a lesser extent, in all the other symptoms, whereas the placebo group showed non appreciable improvement. Results of this clinical study confirm the effectiveness of pharmacological therapy with arginine and natural supplies in young patients with impaired sexual function. There is also the interesting possibility of cyclic repetition of the treatment throughout the year in order to reinforce results and prevent a relapse.


2018 ◽  
Vol 8 (1) ◽  
pp. 11-16
Author(s):  
Faramarz Alibeigi ◽  
Mona Hosseini ◽  
Mohammadreza Shabanian ◽  
Alireza Shabanian ◽  
Gholamreza Shabanian

Introduction: Patient position during surgery is an important issue that can affect vital indices. Objectives: This study was conducted to compare hemodynamic changes, movements, surgery length, and pain during transurethral lithotripsy (TUL) in supine and lateral positions. Patients and Methods: This double-blind clinical trial was conducted on 76 patients who were candidate for TUL, randomized to two groups of 38 for each. In the lateral group, after inducing spinal anesthesia, the patients were positioned lateral and in supine group, the patients were positioned supine immediately after injecting anesthetic. Vital signs were recorded at six intervals; 5 minutes before anesthesia and 1, 5, 10, 15, and 20 minutes after anesthesia. In addition, movements and pain during surgery were assessed. Data analysis was conducted by descriptive statistics, independent t test, and repeated measures ANOVA in SPSS 22. Results: There were significant differences in changes in systolic blood pressure, diastolic blood pressure, and mean arterial pressure at different intervals between the two groups in such a way that hemodynamic stability was greater in the lateral group (P<0.05). There were no significant differences in changes in heart rate at all studied intervals between the two groups (P>0.05). Surgery length, movement and pain during surgery were not significantly different between the two groups (P < 0.05). Conclusion: Hemodynamic changes especially blood pressure were less remarkable in patients undergoing spinal anesthesia in TUL at lateral position than those in supine position. Additionally, no significant differences in patients’ movement and surgery, and surgery length between the two positions was detected.


Sign in / Sign up

Export Citation Format

Share Document